Kuritzkes DR - Search Results

1

Treatment options after virological failure of first-line tenofovir-based regimens in South Africa: an analysis by deep sequencing.

Casadellà M, Noguera-Julian M, Sunpath H, Gordon M, Rodriguez C, Parera M, Kuritzkes DR, Marconi VC, Paredes R. Casadellà M, et al. Among authors: kuritzkes dr. AIDS. 2016 Apr 24;30(7):1137-40. doi: 10.1097/QAD.0000000000001033. AIDS. 2016. PMID: 26807968 Free PMC article.

2

Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients.

Kuritzkes DR, Quinn JB, Benoit SL, Shugarts DL, Griffin A, Bakhtiari M, Poticha D, Eron JJ, Fallon MA, Rubin M. Kuritzkes DR, et al. AIDS. 1996 Aug;10(9):975-81. doi: 10.1097/00002030-199610090-00007. AIDS. 1996. PMID: 8853730 Clinical Trial.

3

Clinical significance of drug resistance in HIV-1 infection.

Kuritzkes DR. Kuritzkes DR. AIDS. 1996 Dec;10 Suppl 5:S27-31. doi: 10.1097/00002030-199612005-00005. AIDS. 1996. PMID: 9030393 Review.

4

Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in lamivudine-experienced patients: results of Adult AIDS Clinical Trials Group protocol 370.

Kuritzkes DR, Bassett RL, Johnson VA, Marschner IC, Eron JJ, Sommadossi JP, Acosta EP, Murphy RL, Fife K, Wood K, Bell D, Martinez A, Pettinelli CB. Kuritzkes DR, et al. AIDS. 2000 Jul 28;14(11):1553-61. doi: 10.1097/00002030-200007280-00011. AIDS. 2000. PMID: 10983642 Clinical Trial.

5

Considerations in choosing a primary endpoint that measures durability of virological suppression in an antiretroviral trial.

Gilbert PB, Ribaudo HJ, Greenberg L, Yu G, Bosch RJ, Tierney C, Kuritzkes DR. Gilbert PB, et al. Among authors: kuritzkes dr. AIDS. 2000 Sep 8;14(13):1961-72. doi: 10.1097/00002030-200009080-00012. AIDS. 2000. PMID: 10997401

6

Comparative analysis of HIV type 1 genotypic resistance across antiretroviral trial treatment regimens.

Gilbert PB, Hanna GJ, De Gruttola V, Martinez-Picado J, Kuritzkes DR, Johnson VA, Richman DD, D'Aquila RT. Gilbert PB, et al. Among authors: kuritzkes dr. AIDS Res Hum Retroviruses. 2000 Sep 20;16(14):1325-36. doi: 10.1089/08892220050140874. AIDS Res Hum Retroviruses. 2000. PMID: 11018852 Clinical Trial.

7

Limited immune restoration after 3 years' suppression of HIV-1 replication in patients with moderately advanced disease.

Valdez H, Connick E, Smith KY, Lederman MM, Bosch RJ, Kim RS, St Clair M, Kuritzkes DR, Kessler H, Fox L, Blanchard-Vargas M, Landay A; AIDS Clinical Trials Group Protocol 375 Team. Valdez H, et al. Among authors: kuritzkes dr. AIDS. 2002 Sep 27;16(14):1859-66. doi: 10.1097/00002030-200209270-00002. AIDS. 2002. PMID: 12351945

8

Drug resistance. Navigating resistance pathways.

Kuritzkes D. Kuritzkes D. AIDS Read. 2002 Sep;12(9):395-400, 407. AIDS Read. 2002. PMID: 12402803

9

Current management challenges in HIV: antiretroviral resistance.

Kuritzkes DR, Boyle BA, Gallant JE, Squires KE, Zolopa A. Kuritzkes DR, et al. AIDS Read. 2003 Mar;13(3):133-5, 138-42. AIDS Read. 2003. PMID: 12728868

10

Management of patients with virologic and metabolic failure.

Kuritzkes DR. Kuritzkes DR. AIDS Read. 2003 Jun;13(6 Suppl):S17-22. AIDS Read. 2003. PMID: 12838743

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

426 results

Search Page